EF Hutton Acquisition Co. I upgraded shares of Quince Therapeutics (NASDAQ:QNCX – Free Report) to a strong-buy rating in a report released on Tuesday, Zacks.com reports.
Quince Therapeutics Stock Performance
NASDAQ QNCX opened at $1.19 on Tuesday. The firm’s fifty day moving average price is $0.74 and its two-hundred day moving average price is $0.80. Quince Therapeutics has a 1 year low of $0.51 and a 1 year high of $1.43. The firm has a market capitalization of $51.43 million, a P/E ratio of -1.57 and a beta of 0.86. The company has a current ratio of 6.15, a quick ratio of 6.15 and a debt-to-equity ratio of 0.29.
Quince Therapeutics (NASDAQ:QNCX – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.18) EPS for the quarter.
Insider Activity
About Quince Therapeutics
Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Featured Articles
- Five stocks we like better than Quince Therapeutics
- Find and Profitably Trade Stocks at 52-Week Lows
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- CD Calculator: Certificate of Deposit Calculator
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.